ArticleBreast cancer (Dove Medical Press)2023

Invasive Breast Cancer with HER2 ≥4.0 and <6.0: Risk Classification and Molecular Typing by a 21-Gene Expression Assay and MammaPrint Plus BluePrint Testing.

Qianming Bai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.